Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explore the Relationship Between Single Nucleotide Polymorphisms and Etoposide Response and Toxicity in Patients With Small Cell Lung Cancer
NCT01064466Phase 3Active, not recruiting
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of etoposide in small cell lung cancer (SCLC). Started Jul 2025; status: active, not recruiting.
02
Drugs
etoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01064466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064466.